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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 100mg
Flibanserin is effective in increasing the number of sexually satisfying events in women with
HSDD.
STUDY DESIGN: Review of three, placebo-controlled trials in which women > 18 years old
with HSDD were treated with either 100mg Flibanserin or a Placebo once daily qhs for 24 weeks
DATA SOURCES: Three randomized, placebo-controlled trials found via PubMed searches and
published in English peer-reviewed journals between 2011-2014
OUTCOMES MEASURED: Outcomes measured were the number of SSE over 4 weeks and
analyzed with Wilcoxon’s rank-sum test.
RESULTS: In DeRogatis et al, 100mg Flibanserin led to increases in the mean (standard error)
SSE 1.6 (0.23) vs 0.80 (0.20) and was proven to be statistically significant (p<0.01). AEs led to
6.8% of 100mg Flibanserin subjects vs. 3.4% of Placebo subjects to discontinue the study
medication. In Katz et al, 100mg Flibanserin led to increases in the mean (standard deviation)
SSE of 2.5(4.6) vs 1.5(4.5) with a p value <0.001. AEs led to 9.76% of Flibanserin subjects vs.
3.47% of subjects on Placebo to discontinue study medications. In Simon et al, 100mg
Flibanserin led to increases in in the mean (standard error) SSE 1.0 (0.1) vs. 0.6 (0.1) and was
statistically significant with p=0.004. 8.1% of Flibanserin subjects discontinued study medication
due to AEs while on 3.1% of Placebo subjects.
CONCLUSIONS: Based on this review, 100mg Flibanserin taken once daily qhs is effective and
well tolerated in treating those with HSDD in both pre- and postmenopausal women. The mean
number of SSE was statistically significant vs. placebo in all three studies.
KEYWORDS: Flibanserin, Hypoactive Sexual Desire Disorder, Women
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INTRODUCTION
Hypoactive Sexual Desire Disorder (HSDD) can be clinically characterized as a lack of
sexual fantasies or desire for sexual activity that leads to marked distress and interpersonal
relationship difficulties.1 Women with HSDD have described feeling less physically and
emotionally satisfied in a relationship as well as generally less happy.1 This paper evaluates three
randomized, double blind, placebo controlled studies that determined if 100mg Flibanserin was
effective at increasing the number of sexually satisfying events (SSE) in women with HSDD.
It is estimated that nearly 10% of all premenopausal women aged 18-55 years old suffer
from a sexual dysfunction disorder.1,2 Women with HSDD are often underreported due to the
difficult nature of diagnosing HSDD and the need to exclude other medical conditions or
psychosocial history.1,2 The exact cause of HSDD is unknown but it is thought that both
biological and psychosocial factors play a role. Biologically, it is thought that there is an
imbalance between the excitatory and inhibitory neurotransmitters thus decreased amounts of
dopamine and norepinephrine and an increased amount of serotonin, which normally has an
inhibitory effect of sexual functioning.1
HSDD is relevant to both patients and the PA practice in that it can impact women’s
quality of life, the amount of money spent on healthcare costs and the number of healthcare visits
each year due to the disorder. Because of its multifactorial etiology, women suffering from
HSDD generally need more outpatient visits, radiological services, laboratory work and
prescription medications to determine its cause.3 Though the exact number of healthcare visits
and cost each year due to HSDD is unknown, one study estimated that women with HSDD spent
16.8% more on healthcare when compared to women without the disorder.3
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Treatment of HSDD includes looking for underlying etiological causes such as
depression or a psychiatric disorder, an arousal disorder, an orgasm disorder, cancer,
uncontrolled hypertension or a side effect from a medication.4 Treatment options vary for
different etiological causes but generally include seeing a psychotherapist or a sex therapist.4
Uncontrolled hypertension can easily be treated with medication and lifestyle changes while side
effects due to a medication can be treated by discontinuing a medication and/or switching to a
different type of medication. Psychotherapy or a sex therapist can help relieve psychological
symptoms in patients with HSDD but oral Flibanserin is the first FDA approved medication
shown to effectively increase the number of SSE in women suffering from HSDD.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not 100mg
Flibanserin is effective in increasing the number of sexually satisfying events in women with
HSDD.
METHODS
All three studies used in this review required a population of adult females over the age of 18
years old who had been diagnosed with generalized HSDD. The intervention was the
implementation of 100mg Flibanserin tablets once daily at bedtime. Comparisons were made
between those taking 100mg Flibanserin tablets and those taking a placebo pill once daily before
bedtime. The outcomes measured were the change in the number of sexually satisfying events
that women reported. All three studies were randomized control trials, double blind and placebo
controlled studies that compared 100mg Flibanserin PO qhs to Placebo PO qhs.
Keywords used when searching for articles included Flibanserin, Hypoactive Sexual
Desire Disorder, and women. All three articles were published in English in peer-reviewed
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journals. Articles were obtained through searching keywords in PubMed and were selected based
on the relevance to the clinical question, being a randomized controlled trial and determining if
the outcomes mattered to patients. Inclusion criteria for the articles included women over the age
of 18 with generalized HSDD > 24 weeks, a stable, communicative, monogamous and
heterosexual relationships for > 1 year with a sexually functional partner who was able to be
present > 50% of every month and women who were willing to engage in sexual activity at least
once per month. The three chosen articles had extensive exclusion criteria but the articles
generally excluded those with a Major Depressive Disorder in the past 6 months, any history of a
suicide attempt, those with other sexual dysfunction or gynecological disorders that could
interfere with the study, a history of substance abuse in the past year or taking medications that
could interfere with sexual dysfunction or cause a drug interaction while taking Flibanserin.
Additional exclusion criteria includes see a psychotherapist in the past year, history of cancer in
the past 10 years, a women who is pregnant or breastfeeding or a partner with HSDD. The
statistics that were utilized and reported in all three studies were mean changes from baseline and
p-values. Table 1 displays the demographics and characteristics of the included studies.
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Table 1: Demographics of Characteristics of included studies
Study

Type

# Pts

Age

Inclusion

Exclusion

w/d

Derogatis
(2011)

Double
Blind,
Placebo
Controlled
RCT

880

Premenopausal
over 18 years
old

Premenopausal
women >18
years of age w/
HSDD > 24
weeks in a
stable
monogamous
heterosexual
relationship >1
year and is
willing to
engage in
sexual activity
at least once a
month

Other sexual dysfunctions 217
or gynecological
disorders, MDD in the
last 6 months or hx of
suicide attempt.
Substance abuse in the
past year or taking
medications that could
interfere with sexual
dysfunction. Seeing a
psychotherapist in past
year. Hx of cancer in the
past 10 years, Pregnant or
breastfeeding women or a
partner w/ HSDD

50mg or
100mg
Flibanserin
qhs

Katz (2013)

Double
Blind,
Placebo
Controlled
RCT

1090

Premenopausal
over 18 years
old

Premenopausal
women >18
years of age w/
HSDD > 24
weeks in a
stable
monogamous
heterosexual
relationship >1
year and is
willing to
engage in
sexual activity
at least once a
month activity
at least once a
month

Other sexual dysfunctions 233
or gynecological
disorders, MDD in the
last 6 months or hx of
suicide attempt.
Substance abuse in the
past year or taking
medications that could
interfere with sexual
dysfunction. Seeing a
psychotherapist in past
year. Hx of cancer in the
past 10 years, Pregnant or
breastfeeding women or a
partner w/ HSDD

100mg
Flibanserin
qhs

Simon
(2014)

Double
Blind,
Placebo
Controlled
RCT

949

Postmenopausal
women of any
age w/ at least
one ovary

Naturally
postmenopausal
women of any
age with HSDD
lasting 6
months or more
and those in a
stable
monogamous
relationship >1
year

Beck Inventory
Depression score of >14
or suicidal attempts, other
sexual dysfunctions or
gynecological disorders
or
taking medications that
could interfere with
sexual dysfunction or
cause drug interactions

Flibanserin
100mg qhs

185

Intervention
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OUTCOMES MEASURED
A SSE is defined as “sexual intercourse, oral sex, masturbation, or genital stimulation by
a partner.”1 For all three studies, women were required to keep an eDiary and record their sexual
activity and whether this activity was satisfying.1 If women had sexual activity she would
respond to whether or not it was satisfying by responding yes or no. All three studies used a
Wilcoxon’s rank-sum test for analyzing whether sexual activity was considered a SSE.
RESULTS
All three studies compared the use of 100mg Flibanserin with placebo for the
symptomatic treatment of HSDD. Two trials were in women > 18 years and older who were
premenopausal while the third study used women > 18 years old who were postmenopausal. All
three studies were randomized control trials in which the data was continuous and not converted
into dichotomous data.
The DeRogatis et al study used pre menopausal women >18 years old and had a very
large list of exclusion criteria (Table 1) that excluded a variety of women with relationship
problems, gynecological disorders other than HSDD, exclusion of a variety of medications that
could interfere with the study drug and any pregnancy or mental health concerns. Due to
HSDD’s multifactorial etiology, researchers felt that many factors had to be excluded that could
affect any aspect of low libido, other than HSDD, such as hormonal changes, and any
interactions with the study drug and/or mental health concerns. In this study the subjects were
randomly selected to be in one of three groups: 50mg Flibanserin, 100mg Flibanserin or Placebo
all taken qhs, but this paper will solely focus on the 100mg Flibanserin group for consistency
across all three studies. Results showed that 100mg Flibanserin taken qhs for 24 weeks increased
the number of SSE in women when compared with the Placebo control group and the results can

Frymoyer, Flibanserin and HSDD 6
be found in Table 2.1 The number of SSE was greater in the 100mg Flibanserin group at 3.0±2.8
when compared to the Placebo group at 2.7±2.8 over a 4 week time period. In Table 3, the mean
change from baseline of SSE was determined to be 0.8 for the Placebo group and 1.6 for the
100mg Flibanserin group with a p value <0.01, showing statistical significance. The number of
women who reported an Adverse Event (AE) from taking the study medication is displayed in
Table 4. 59.3% of women in the Placebo group reported an AE with 3.4% of these women
discontinuing the medication while nearly 66.6% of women in the 100mg Flibanserin group
reported an AE and 11.4% discontinued the study drug due to these events.
Table 2: Number of SSE in DeRogatis et al Study1
Type of Treatment

# of SSE over 4 weeks

100mg Flibanserin

3.0±2.8

Placebo

2.7±2.8

Table 3: Mean change from Baseline of SSE1
Type of Treatment

P value

100mg Flibanserin

Mean Change from Baseline
(Standard Error)
1.6 (0.23)

Placebo

0.8 (0.20)

P<0.01

Type of Treatment

Percent of AE reported

Percent who discontinued due to
AE

100mg Flibanserin
Placebo

66.6%
59.3%

3.4%
11.4%

P<0.01

Table 4: AE analysis1

The Katz et al study also studied women > 18 years old who were premenopausal,
diagnosed with HSDD and included identical inclusion and exclusion criteria to the DeRogatis et
al study. In this study, subjects were also randomized to a 100mg Flibanserin group or a Placebo
group and took the study medication qhs for 24 weeks. Results showed that the number of SSE
was similar in both the Placebo group and the 100mg Flibanserin group as shown in Table 5. The
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Placebo group had 2.7 SSE while the Flibanserin group had 2.5 SSE over a 4 week time period.
The mean change from baseline of the number of SSE between the Placebo group and the 100mg
Flibanserin group was statistically significant with p < 0.001 and the results are shown in Table
6. The Flibanserin group showed a mean change in baseline of the number of SSE of 2.5 when
compared to the Placebo group of 1.5. Table 7 shows the number of AE in each treatment group
and the Placebo group had 50.5% of women reporting an AE and nearly 62.2% of women taking
100mg Flibanserin reporting an AE. Approximately 3.7% of the placebo group discontinued due
to an AE while 9.6% of 100mg Flibanserin discontinued the study.
Table 5: Number of SSE in Katz et al Study2
Type of Study

# of SSE over 4 weeks (SD)

100mg Flibanserin

2.5(2.5)

Placebo

2.7(2.9)

Table 6: Mean change from Baseline of SSE2
Type of Study

Mean change from Baseline
(Std Deviation)

P value

100mg Flibanserin
Placebo

2.5(4.6)
1.5(4.5)

P <0.001
P<0.001

Type of Study

% of AE reported

100mg Flibanserin

62.2%

Percent who discontinued due
to AE
9.6%

Placebo

50.5%

3.7%

Table 7: AE Analysis2

The Simon et al study used postmenopausal women diagnosed with HSDD, unlike the
previous two studies which looked at premenopausal women. Women were blindly randomized
to two different groups which took either Placebo or 100mg Flibanserin qhs daily for 24 weeks.
The inclusion criteria included postmenopausal women with at least one ovary and the other
inclusion criteria included in Table 1. Exclusion criteria included similar criteria in both of the
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previous studies discussed and is also included in Table 1. The number of SSE between the
Placebo group and the 100mg group were similar and are displayed in Table 8. Both the placebo
group and the Flibanserin group showed that the number of SSE over a 4-week period was 2.0.
The placebo group showed a mean change of SSE from baseline of 0.6 while the Flibanserin
group showed a 1.0 mean change with a p-value equal to 0.004, showing statistical significance
and this data is included in Table 9. The number of AE, shown in Table 10, reported in the
Placebo group was 51.7% with 3.5% of women dropping out compared to the Flibanserin group,
which reported 63.4% of AE and 8.1% of women dropping out of the study.
Table 8: Number of SSE in Simon et al Study5
Type of Study

# of SSE over 4 weeks (SD)

100mg Flibanserin

2.0 (2.2)

Placebo

2.0 (2.4)

Table 9: Mean change from Baseline of SSE5
Type of Study
100mg Flibanserin
Placebo

Mean change from Baseline
(Std Deviation)
1.0 (0.1)
0.6 (0.1)

P value
P =0.004
P=0.004

Table 10: AE Analysis5
Type of Study

% of AE reported

100mg Flibanserin

63.4%

Percent who discontinued due
to AE
8.1%

Placebo

51.7%

3.5%

DISCUSSION:
Flibanserin, or its trademark name Addyi, is a serotonin 1A receptor agonist and a
serotonin 2A receptor antagonist that is the only FDA approved drug to treat premenopausal
women diagnosed with HSDD.6 Though the drug is said to improve sexually satisfying events
and improve sexual desire, it is still widely unknown the mechanism the drug takes to improve
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symptoms.6 Flibanserin is contraindicated in those with liver impairment, those who drink
alcohol and those taking moderate to severe CYP3A4 inhibitor medications due to drug
interactions.7 This drug does contain a Boxed Warning that highlights the risk of both
hypotension and syncope especially in those consuming alcohol while using the medication.7
The FDA approved Flibanserin with a risk evaluation and mitigation strategy (REMS), which
requires both physicians and pharmacists that would prescribe this medication to undergo
training to ensure adequate patient counseling on the risk of using alcohol.7 Flibanserin was
previously used in depression studies and failed to show efficacy but subjects reported having a
decreased sexual dysfunction, which led to studies looking at the use of this drug and HSDD.6
Adverse Events were reported in all three studies but a minimal amount of subjects opted
out of the study due to the AE as seen in Table 4, 7 and 10. Most AEs were mild to moderate
with no severe AEs due to taking 100mg Flibanserin or the Placebo. The most common side
effects included dizziness, somnolence and nausea.1,2,3
All three studies analyzed showed an increase in the number of SSE in pre- and
postmenopausal women with HSDD with the use of 100mg Flibanserin versus Placebo. In the
Katz et al study, though 100mg Flibanserin was shown to increase the number of SSE, the
magnitude of improvement was found to be less than the DeRogatis et al study or the Katz et al
study. Postmenopausal women generally have a higher risk of dyspareunia and sexual arousal
disorders which could have led to a lesser improvement of SSE in postmenopausal women.
This review supports the use of 100mg Flibanserin in the treatment of HSDD but there a
considerable amount of limitations to all three studies. In both DeRogatis et al and Katz et al
extensive exclusion criteria were used such as women in unstable relationships, those diagnosed
with depression, those with a partner suffering from sexual dysfunction and a long list of
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contraindicated medications. In Katz et al, nearly 1/3 of all patients screened were ineligible due
to exclusion criteria.2 In Simon et al, subjects were excluded with similar criteria except the list
of contraindicated medications was greatly reduced. Though exclusion criteria was used to rule
out other causes of decreased libido, it’s possible that many women can suffer from HSDD in
other settings and that these studies were not fully representative of all women.
CONCLUSION:
Based on this systematic review and chosen studies, 100mg Flibanserin is an effective
treatment for premenopausal and postmenopausal women diagnosed with HSDD. The data found
in these three studies are consistent with the beneficial effects of Flibanersin as well as its overall
safety. No serious AEs were judged by researchers to be related to study medications; therefore,
it should be a consideration when looking to treat patients for HSDD. Though, no serious AEs
were found, there are some limitations to be considered when prescribing this medication such as
the use of alcohol and Flibanserin, use of CYP3A4 drugs or liver dysfunction. Physicians should
be well informed of the contraindications as well as the drug interactions of Flibanserin before
prescribing it.
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